// App-Quantinova.ai

604 : Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).

Researchers

Presenter

  • Natalie Ngoi

Principal Investigators

  • Emma L. Scholefield

  • Vamsi Parini

  • Richard S.P. Huang

  • Tyler Janovitz

  • Natalie Danziger

  • Mia Alyce Levy

  • Shubham Pant

  • Milind M. Javle

  • Jeffrey S. Ross

  • Jordi Rodon Ahnert

Medical Centers

  • Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of Strathclyde, Glasgow, United Kingdom

  • Foundation Medicine, Inc, Cambridge, MA

  • Foundation Medicine, Inc, Cambridge, MA

  • Foundation Medicine, Inc., Boston, MA

  • Vanderbilt University, Nashville, TN

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Programmed death-ligand 1

  • Microsatellite instability

  • Tumor mutational burden

Drug/Treatment

  • methionine

  • Arginine hydrochloride

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved